evolocumab
amgen
['fourier', 'cardio']
fantastic results of the #fourier_ole extension trial that at 5 yrs, although both arms are on open label #pcsk9_inhibitor the initially randomised to active therapy continue to diverge into better outcomes including survival #esccongress2022 #cardiotwittter
Professor of Cardiology @SheffieldHosp & @sheffielduni,  @RCPEdin Central England Council Member, Fellow @RCPLondon, @escardio & #HFA_ESC. Views are my own.